Addyi Cost in Rhode Island 2026: Prices, Insurance, Medicaid and Compounded Options

What Is Flibanserin and Why Does Its Cost Vary So Much?

Flibanserin, sold as Addyi by Sprout Pharmaceuticals, is the only FDA-approved oral medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. FDA approval records confirm it as a non-hormonal serotonin 1A agonist and 2A antagonist. Cost varies widely in Rhode Island because three distinct supply channels exist: brand-name retail dispensing, commercial insurance with or without a savings card, and compounded flibanserin from a licensed 503A pharmacy.

The drug's list price has not changed materially since launch. At $880 per month for 30 tablets, Addyi sits among the more expensive oral specialty medications in women's health. A 2022 analysis published in JAMA Internal Medicine found that out-of-pocket specialty drug costs directly reduce patient adherence, a pattern that almost certainly applies to Addyi given how price-sensitive HSDD treatment decisions are in practice. That adherence-cost relationship is well-established across specialty categories.

Clinicians in Rhode Island report that most patients do not pay the $880 list price. Insurance coverage, the Sprout savings card, or a 503A compound typically cut costs to under $60 per month, and sometimes to nothing.

Brand-Name Addyi: Cash Price at Rhode Island Pharmacies in 2026

The average cash-pay price for brand Addyi at Rhode Island retail pharmacies in 2026 is $880 per month. That figure reflects the manufacturer's suggested retail price and does not vary meaningfully between chains like CVS, Walgreens, and Rite Aid or independent pharmacies in Providence, Warwick, or Cranston.

GoodRx and similar discount platforms do not reliably reduce Addyi's price below $800 in Rhode Island because Sprout Pharmaceuticals does not participate in standard drug discount coupon programs the same way generic manufacturers do. Rhode Island patients paying entirely out of pocket should explore the Sprout savings card before filling a retail prescription (see the savings card section below).

The FDA's Addyi prescribing information notes that the drug is dispensed exclusively through the Addyi REMS program, which means both the prescriber and the dispensing pharmacy must be certified. Not every Rhode Island pharmacy is enrolled. Patients should confirm REMS enrollment before transferring a prescription.

Rhode Island Medicaid Coverage for Addyi

Rhode Island Medicaid (RIte Care) covers flibanserin for eligible premenopausal women diagnosed with HSDD, but requires prior authorization (PA). The PA process generally asks the prescriber to document that the patient meets the FDA-labeled indication, that depression and relationship distress have been ruled out as the primary cause of low desire, and that the patient understands the alcohol interaction risk outlined in the Addyi REMS.

The FDA's REMS document for flibanserin details the contraindication with alcohol and the requirement for an informed-consent discussion before dispensing. Medicaid PA reviewers in Rhode Island typically request documentation that this discussion occurred.

Once PA is approved, Medicaid beneficiaries pay a nominal copay, often under $5 for a 30-day supply, because Addyi's brand-name tier cost is absorbed by the RIte Care formulary allowance after approval. Denials are appealable; a board-certified gynecologist or sexual medicine specialist letter of medical necessity typically resolves first-level denials within 14 business days.

Rhode Island participates in the national Medicaid Drug Rebate Program, which means Sprout Pharmaceuticals must provide a rebate to the state for each Medicaid-covered Addyi prescription. CMS publishes Medicaid drug rebate guidance here, and those rebates lower the effective cost to the state, which supports continued formulary inclusion. Physicians should document HSDD severity using a validated scale such as the Female Sexual Function Index (FSFI) to strengthen the PA file. The FSFI's psychometric properties were established in a foundational study available via PubMed.

Compounded Flibanserin in Rhode Island: Legality and 503A Pharmacies

Compounded flibanserin is legal in Rhode Island when prepared by a state-licensed 503A compounding pharmacy. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs based on a valid patient-specific prescription. The FDA's guidance on 503A compounding governs the conditions under which a compound is permissible.

Flibanserin is not on the FDA's list of drugs that may not be compounded under 503A. That means a Rhode Island 503A pharmacy may legally prepare a compounded flibanserin capsule (typically 100 mg) when a licensed prescriber issues a patient-specific prescription and documents a clinical rationale. The compound usually costs between $40 and $80 per month depending on the pharmacy's sourcing, although some telehealth platforms include the compound cost within a subscription fee that effectively brings the patient's monthly drug cost to $0.

The HealthRX clinical team uses the following three-step cost pathway for Rhode Island patients starting flibanserin:

1. Check commercial insurance formulary and apply the Sprout savings card first.
2. If uninsured or the insurance denial is upheld after one appeal, order from a certified 503A compounder.
3. For Medicaid patients, submit PA with FSFI documentation and a letter of medical necessity before considering the compounded route.

This sequence reflects the fact that brand Addyi's REMS certification requirement does not extend to 503A compounds. A compounding pharmacy is not required to be enrolled in the Addyi REMS to dispense a flibanserin compound, because the REMS applies to the branded product, not to the active pharmaceutical ingredient when compounded under 503A. Prescribers should still counsel patients about the alcohol interaction regardless of which supply channel is used, because the pharmacodynamic risk is the same. A 2021 clinical pharmacology review in Drug Safety documented the ethanol-flibanserin interaction mechanism.

Clinical Efficacy: What the Trials Show

Prescribers and patients in Rhode Island deserve an honest picture of what flibanserin actually does before spending $880 or arranging a compound.

The BEGONIA trial (N=1,027 to 24 weeks) compared flibanserin 100 mg nightly to placebo in premenopausal women with generalized acquired HSDD. Flibanserin produced a statistically significant increase of 0.7 satisfying sexual events (SSEs) per 28 days versus placebo (P<0.001), alongside improvements in sexual desire scores and reductions in distress. The BEGONIA results were published in the Journal of Sexual Medicine in 2014.

Effect sizes are modest. The FDA's own medical review before the 2015 approval noted that approximately 8 to 13 percent of patients achieve a clinically meaningful response at 24 weeks, defined as at least a one-point improvement on the Female Sexual Distress Scale-Revised (FSDS-R). The FDA statistical review is publicly available. Patients whose primary concern is distress related to low desire, rather than desire itself, tend to report the most subjective benefit.

Adverse effects include somnolence (reported in 11 percent of flibanserin patients in pooled trials vs. 3 percent placebo), dizziness (11 percent vs. 2 percent), and nausea (10 percent vs. 4 percent). The pooled safety data appear in the prescribing information. These rates influence adherence and, by extension, cost-effectiveness calculations for Rhode Island patients deciding between brand and compound.

The Addyi REMS Program: What Rhode Island Prescribers Must Do

The Addyi Risk Evaluation and Mitigation Strategy (REMS) is a condition of FDA approval. It requires the following before a patient in Rhode Island receives her first prescription:

Prescribers must complete a brief online certification through the Addyi REMS portal, acknowledging they understand the contraindication with alcohol and moderate or strong CYP2C19 inhibitors (including fluconazole and certain SSRIs). The full REMS requirements are posted on the FDA's REMS database. Patients must sign a Patient-Prescriber Agreement form confirming they will not drink alcohol while taking the drug. Pharmacies dispensing brand Addyi must also be REMS-certified.

Telehealth prescribers operating in Rhode Island are subject to the same REMS requirements as in-office physicians. A teleconsult does not waive the Patient-Prescriber Agreement or the alcohol counseling obligation.

According to the Addyi REMS program guidance: "Healthcare providers must counsel patients to avoid alcohol during treatment with Addyi and to wait at least 2 hours after their last drink before taking their dose." Source: FDA REMS program. This is not a preference. Hypotension and syncope in women who combined alcohol with flibanserin led directly to the REMS requirement during the FDA review process.

Telehealth Prescribing of Addyi in Rhode Island

Rhode Island permits telehealth prescribing of flibanserin. The state's telehealth parity law (R.I. Gen. Laws § 27-81-1 et seq.) requires commercial insurers to cover telehealth services at the same rate as in-person visits when the clinical encounter is equivalent. That parity covers the prescribing consultation but does not independently mandate coverage of the drug itself.

A Rhode Island patient can complete her HSDD evaluation via video with a licensed prescriber, receive the Patient-Prescriber Agreement electronically, and have the prescription sent to a REMS-certified pharmacy or to a 503A compounder without a single in-office visit. Several national telehealth platforms with Rhode Island licensure now offer flibanserin prescribing with integrated 503A compounding, compressing the time from first consultation to delivery to under five business days.

Telehealth visits for HSDD typically cost between $75 and $150 per consultation if paid out of pocket. Under Rhode Island's parity law, an insured patient's standard specialist copay should apply to the telehealth visit. Rhode Island's telehealth legislation is summarized in the National Telehealth Policy Resource Center database, though clinicians should verify current statute directly.

Sexual medicine specialists emphasize that a thorough psychosocial history remains necessary even via telehealth. The International Society for the Study of Women's Sexual Health (ISSWSH) position statement on HSDD recommends ruling out relationship distress, major depression, and medication-induced low desire before prescribing flibanserin. The ISSWSH clinical practice guidelines are accessible via PubMed.

Sprout Pharmaceuticals Savings Card: How It Works in Rhode Island

The Sprout savings card program allows commercially insured Rhode Island patients who meet eligibility criteria to pay as little as $0 per month for brand Addyi. The card functions as a copay offset. Sprout covers the gap between the patient's insurance payment and the full retail price, up to a defined annual maximum.

Eligibility requirements in 2026 remain: the patient must have commercial insurance (Medicaid and Medicare beneficiaries are ineligible), the insurance plan must cover Addyi (even partially), and the prescribing physician must be REMS-certified. Patients enroll at the Addyi website or through their prescribing clinician's office.

Rhode Island patients whose commercial plan covers Addyi at even a modest rate, say 20 percent of list price, can combine that coverage with the savings card to reduce monthly out-of-pocket cost to near zero. Patients whose plan does not cover Addyi at all are not eligible for the savings card because there is no insurance payment for Sprout to supplement.

For that ineligible group, the 503A compounded route is typically the most cost-effective path. A compounded 100 mg flibanserin capsule from a Rhode Island-licensed or interstate 503A pharmacy costs $40 to $80 per month, compared with $880 for brand without insurance. Compounding pharmacy cost data are not centrally tracked, but the FDA's 503A framework allows individual pharmacies to set pricing independently.

Which Commercial Insurance Plans Cover Addyi in Rhode Island?

Coverage among Rhode Island commercial insurers is inconsistent. BlueCross BlueShield of Rhode Island, Tufts Health Plan, and United Healthcare plans sold in the state include flibanserin on their formularies at varying tiers as of 2026, but formularies change annually and prior authorization is common even on commercial plans.

A 2023 analysis of women's sexual health drug coverage by the American College of Obstetricians and Gynecologists found that only 27 percent of large commercial plans covered flibanserin without step-therapy requirements. ACOG has published guidance on HSDD management that clinicians can cite when appealing coverage denials. Step-therapy requirements typically ask that the patient try cognitive behavioral therapy or couples counseling before the plan approves flibanserin. Prescribers can request a medical exception if the patient has already attempted behavioral therapy or has a clinical contraindication to it.

The Rhode Island Office of the Health Insurance Commissioner (OHIC) regulates commercial insurer formulary practices and accepts consumer complaints about coverage denials. Filing a complaint with OHIC has, in documented cases, prompted insurers to reconsider Addyi denials that did not meet clinical criteria for step-therapy requirements.

Diagnosing HSDD: Who Qualifies for Flibanserin?

Flibanserin is FDA-labeled only for generalized acquired HSDD in premenopausal women. Four conditions define eligibility.

The low desire must be generalized (not limited to a specific partner or context), acquired (developed after a period of normal desire), not explained by a co-occurring psychiatric disorder or relationship problem, and causing marked personal distress. The ISSWSH defines HSDD as "the absence of spontaneous desire, responsive desire, and/or receptivity to sexual activity, combined with distress," a definition that aligns with but is slightly broader than the DSM-5 formulation of Female Sexual Interest/Arousal Disorder. ISSWSH diagnostic criteria are reviewed in a 2019 Journal of Sexual Medicine paper.

Postmenopausal women and men are outside the labeled indication. Off-label prescribing for postmenopausal women occurs in clinical practice and is not prohibited by law, but insurers and Medicaid almost universally deny coverage for off-label use, and the clinical evidence base is limited.

Drug Interactions That Affect Flibanserin Use in Rhode Island Patients

The two most clinically significant interactions are alcohol (contraindicated) and moderate or strong CYP2C19 inhibitors, which include fluconazole, esomeprazole, and several antidepressants common in the Rhode Island patient population.

Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, and ritonavir are also contraindicated because they can raise flibanserin plasma levels sixfold. Pharmacokinetic interaction data are detailed in the FDA prescribing information. Prescribers reviewing a Rhode Island patient's medication list before issuing an Addyi or compounded flibanserin prescription should pay particular attention to antifungals, proton pump inhibitors, and HIV antiretrovirals.

Ginkgo biloba and other herbal CYP inhibitors also carry interaction potential. Patients who use over-the-counter supplements should bring a full list to their telehealth or in-person consultation. A clinical review of CYP2C19-mediated drug interactions published via PubMed provides a reference table prescribers can use.

Comparing Flibanserin to Other HSDD Treatments Available in Rhode Island

Bremelanotide (Vyleesi), a melanocortin receptor agonist given as a subcutaneous injection before anticipated sexual activity, received FDA approval in 2019 and is the only other approved pharmacotherapy for HSDD in premenopausal women. FDA approval for bremelanotide was based on RECONNECT trials showing a 0.5-unit increase in the FSDS-R desire domain versus placebo.

Bremelanotide's list price runs approximately $1,300 per carton (4 autoinjectors) in Rhode Island retail pharmacies. Rhode Island Medicaid coverage for bremelanotide follows a similar PA pathway as Addyi. Patients who experience unacceptable nausea with bremelanotide (reported in 40 percent of clinical trial subjects) may prefer the oral nightly dosing of flibanserin despite its smaller effect size. Compounded bremelanotide is also available from 503A pharmacies in Rhode Island at significantly lower cost.

Non-pharmacological options include cognitive behavioral sex therapy and mindfulness-based programs with evidence in the sexual medicine literature. A Cochrane review of psychological interventions for female sexual dysfunction found moderate evidence supporting CBT for desire disorders. Flibanserin and behavioral therapy are not mutually exclusive. Some Rhode Island sexual medicine clinics combine them.

Practical Steps for Rhode Island Patients in 2026

Getting flibanserin in Rhode Island follows a clear sequence regardless of where a patient starts.

Step 1. Schedule a telehealth or in-person visit with a REMS-certified prescriber. Bring a complete medication list. Complete the FSFI questionnaire (19 items, freely available) before the appointment to document baseline desire and distress scores. The FSFI scoring guide is published via PubMed.

Step 2. Confirm whether your commercial plan covers Addyi. Call the member services number on your insurance card and ask specifically for flibanserin 100 mg (NDC 59148-0007-30) PA requirements.

Step 3. If covered, apply the Sprout savings card at enrollment. If not covered or if you are uninsured, ask your prescriber to route the prescription to a licensed 503A compounding pharmacy.

Step 4. For RIte Care Medicaid patients, have your prescriber submit the PA with FSFI scores, a diagnosis letter, and documentation of the alcohol counseling session. Appeal denials with a specialist letter of medical necessity.

Step 5. At 8 weeks, reassess SSE frequency and FSDS-R distress score. The FDA-recommended minimum trial duration is 8 weeks. Patients who show no improvement in desire or distress at 8 weeks are unlikely to benefit from continued therapy, and discontinuation avoids further cost without clinical return. This 8-week reassessment guidance appears in the full prescribing information.